Skip to content
PeptideWiki.bio

Metabolic

Metreleptin

Also called Myalept

InjectableEvidence AEvery day
Half-life
4hours
Typical vial
11.3mg
Research amounts
2.5–10mg

per administration

Common schedule
Every day
Tested in people

A human trial worked out how much to take and how often, so a dosing schedule is shown.

Licensed as a medicine in the US and EU.

Quick start

Metreleptin at a glance — the figures, plus how it's commonly run. Reference only, not medical advice.

Typical dose
2.5–10 mg per administration
How often
Every day
Where
Subcutaneous — abdomen, thigh, or upper arm Sites and rotation
Time to steady level
~20 hours — about five half-lives
Storage
Dry vial kept cold and dark; a mixed vial in the fridge at 2–8 °C. Details

A research and community reference, not medical advice. Figures are descriptive, vary between sources, and are not a recommendation for use.

Work out your draw

These numbers are a starting point — change any of them.

Vial label

Copy this into your label printer.

Published research contexts for Metreleptin describe 2.510 mg per administration. Descriptive only, not a recommendation.

Roughly 4 hours in plasma, consistent with once-daily administration.

Dosing schedule

How Metreleptin is commonly stepped up, for reference only.

These are commonly-discussed research protocols shared for educational reference. This is not medical advice and is not a substitute for guidance from a qualified professional.

PhaseAmountFrequencyRoute
MaintenanceA recombinant leptin analog dosed by body weight; the licensed label titrates within this range.2.5–10 mg (weight-based)Once dailySubQ

Modelled level — every day

1× is the peak after a single dose.

Steady-state peak
1.02× single dose

Read off the modelled curve, not an even-interval formula

Time to steady state
20hours

About five half-lives

Administrations
7/ week

Where these numbers come from

  • Metreleptin (Myalept / Myalepta) label and lipodystrophy studiesLicensed leptin analog given once daily by body weight in generalized and partial lipodystrophy research.

Next steps